RxDoctor Payments Data

Nataliya Rozenvayn, NP

Psychiatric/Mental Health · Natick, MANPI 1487178240

Payments from drug & device makers

$744in general payments, 2019–2025

Across 33 payments — averaging $22.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$167
  • AbbVie$159
  • E.r. Squibb & Sons, L.L.C.$153
  • Lundbeck LLC$84
  • Vanda Pharmaceuticals Inc.$53
  • Collegium Pharmaceutical, Inc.$38
  • plus $90 from 3 others

What the payments were for

  • Food & beverage$744100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$744 in reported general payments places this provider in the 70th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$91,237
Medicare patients
87
Services billed
782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole100$149,623
Lurasidone Hcl77$36,343
VraylarCariprazine Hcl12$16,889
Aripiprazole125$15,902
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine456$12,032
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine124$5,955
Gabapentin303$5,079
Paliperidone ErPaliperidone31$5,030
Desvenlafaxine Succinate ErDesvenlafaxine Succinate46$4,858
Fluphenazine Hcl14$4,309
Adderall XrDextroamphetamine/Amphetamine19$4,201
Clonazepam338$2,907
Ramelteon35$2,639
Quetiapine Fumarate ErQuetiapine Fumarate39$2,530
Olanzapine65$2,526

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$167$149,623100 claims
AbbVieVraylar$159$16,88912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Natick

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →